Why are Agilent Technologies shares up 50%?

Agilent Technologies shares have surged approximately 50% from their April lows due to a turnaround in the life sciences sector and a solid recent quarterly performance.

What is Danaher's stock performance and outlook?

Danaher shares are up 30% from April lows, with analysts projecting mid-single-digit revenue growth into 2026 and a price target of $270.

What caused the post-Covid slump in life science stocks?

Clients over-ordered bioprocessing equipment and lab instruments during the pandemic boom, leading to a demand bust once the surge subsided.

Home / Business and Economy / Life Science Stocks Rebound: Danaher, Agilent Lead the Charge

Life Science Stocks Rebound: Danaher, Agilent Lead the Charge

3 Dec

•

Summary

Agilent Technologies stock has risen approximately 50% from its April lows.
Danaher shares have climbed 30% from their April lows since September.
Morgan Stanley initiated coverage with a buy rating and a $270 price target.

Life Science Stocks Rebound: Danaher, Agilent Lead the Charge

The life sciences stock sector is demonstrating a robust recovery, signaling better prospects ahead for companies like Danaher. Agilent Technologies, a key player, exemplifies this turnaround, with its stock price climbing approximately 50% from its April lows. This industry-wide resurgence suggests a positive shift after a challenging post-pandemic period.

Companies that supply tools and technologies to pharmaceutical and biotech firms, often termed 'arms dealers' of the life science industry, are now seeing renewed interest. Danaher, along with peers like Thermo Fisher, Revvity, and Waters, is benefiting from this trend. After a period of over-ordering and subsequent demand contraction, the industry is normalizing.

Danaher's stock has shown significant gains, rising 30% from its April lows, largely since late September. Wall Street's enthusiasm has been reignited by strong quarterly results and guidance. Analysts at Morgan Stanley initiated coverage with a buy-equivalent rating, projecting mid-single-digit revenue growth for Danaher into 2026, and assigned a $270 price target.